HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sfondrini, L. Articles by Balsari, A. Search for Related Content PubMed PubMed Citation Articles by Sfondrini, L. Articles by Balsari, A.

Antitumor Activity of the TLR-5 Ligand Flagellin in Mouse Models of Cancer¹

Lucia Sfondrini^2,*, Anna Rossini^2,, Dario Besusso, Andrea Merlo, Elda Tagliabue, Sylvie Mènard and Andrea Balsari^3,*

^* Institute of Pathology, University of Milan, Milan, Italy; and Molecular Targeting Unit, Department of Experimental Oncology, Istituto Nazionale Tumori, Milan, Italy

Flagellin, the structural protein subunit of the bacterial flagellum, is specifically recognized by TLR-5 and has potent immunomodulatory effects. The antitumor effects of purified Salmonella typhimurium flagellin were evaluated in mice transplanted s.c. with a weakly immunogenic murine tumor or with its variant stably transfected to express the highly antigenic human HER-2 oncoprotein. Peritumoral administration of flagellin 8–10 days after tumor implantation did not affect the growth rate of the weakly immunogenic tumor but significantly inhibited growth of the antigenic variant tumor. In contrast, flagellin administered at the time of implantation of the antigenic tumor led to accelerated tumor growth. These contrasting effects of flagellin on tumor growth correlated with the type of immune response induced; i.e., late flagellin administration was associated with an increased IFN-:IL-4 ratio and the decreased frequency of CD4⁺CD25⁺ T regulatory cells, whereas flagellin treatment at the time of tumor implantation decreased the IFN-:IL-4 ratio and increased CD4⁺CD25⁺ T cell frequency. When the early flagellin treatment was combined with administration of CpG-containing oligodeoxynucleotides, tumor growth was completely suppressed, indicating synergy between flagellin and CpG-containing oligodeoxynucleotides. Together, these data provide evidence that flagellin can have contrasting effects on tumor growth.

This article has been cited by other articles:

				C.-H. Lee, C.-L. Wu, and A.-L. Shiau Toll-like Receptor 4 Mediates an Antitumor Host Response Induced by Salmonella choleraesuis Clin. Cancer Res., March 15, 2008; 14(6): 1905 - 1912. [Abstract] [Full Text] [PDF]

				V. Andreani, G. Gatti, L. Simonella, V. Rivero, and M. Maccioni Activation of Toll-like Receptor 4 on Tumor Cells In vitro Inhibits Subsequent Tumor Growth In vivo Cancer Res., November 1, 2007; 67(21): 10519 - 10527. [Abstract] [Full Text] [PDF]